Post date June 20, 2023 Experience Editas Medicine $125 million follow-on offering The stock is listed on the Nasdaq Global Select Market
Post date June 13, 2023 Experience Akoya Biosciences $50 million follow-on offering The stock is listed on Nasdaq
Post date June 12, 2023 Experience Ionis Pharmaceuticals $575 million convertible senior notes offering The 1.75% convertible senior notes are due 2028
Post date June 5, 2023 Experience Oculis Holding $40.25 million debut equity offering The shares are listed on the Nasdaq Global Market
Post date June 1, 2023 Experience TScan Therapeutics $140.6 million stock and pre-funded warrants offering The stock is listed on the Nasdaq Global Market
Post date May 18, 2023 Experience Emergent BioSolutions $150 million at-the-market offering The shares are listed on the NYSE
Post date May 17, 2023 Experience Forbion European Acquisition combination with enGene We are advising Forbion European Acquisition on its de-SPAC transaction
Post date May 12, 2023 Experience GSK exclusive licensing agreement with Scynexis We advised GSK on the transaction
Post date May 12, 2023 Experience Olema Pharmaceuticals $100 million at-the-market offering The shares are listed on the Nasdaq Global Select Market
Post date May 9, 2023 Experience ACELYRIN $621 million IPO The stock is listed on the Nasdaq Global Select Market